Adagene (ADAG)
(Delayed Data from NSDQ)
$2.21 USD
0.00 (0.00%)
Updated Oct 15, 2024 09:35 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADAG 2.21 0.00(0.00%)
Will ADAG be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ADAG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADAG
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
ADAG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Other News for ADAG
Buy Rating Affirmed on Adagene: Promising ADG126 Clinical Data and Market Underappreciation
Adagene’s ADG126 Shows Promise in MSS CRC Therapy
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody? ADG126 (Muzastotug) in Combination with KEYTRUDA? (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Adagene to Participate in Investor Conferences in September